The fly in the ointment imo comes as the drug progresses as you go it alone and expenses accumulate and dilution becomes more of a factor. The other thing I feel is that if the drug is approved you will need a partner to market it and at this point the leverage imo is squarely in the partner's court as the smaller biotech has likely exhausted resources and must take what offer the partner gives to try recoup expenses. I would feel much better if we were partnered with a large player with deep pockets. I just see the MNKD Afreza example as a good warning to heed. This is just my opinion and I'm sure most will disagree.
ANP Price at posting:
29.5¢ Sentiment: Hold Disclosure: Held
